Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - What's Next?

Key Points

• Telix Pharmaceuticals (NASDAQ:TLX) experienced a significant increase in trading volume, with 88,811 shares traded, marking a 12% rise compared to the previous session.
• Analysts have mixed opinions on the stock; Citigroup issued a "buy" rating with a $22 price target, while Weiss Ratings maintained a "sell" rating, resulting in a consensus rating of "Moderate Buy."
• Hedge funds have recently purchased new positions in Telix Pharmaceuticals, with notable investments totaling over $1 million from various institutional investors in the first and second quarters.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares saw strong trading volume on Wednesday . 88,811 shares were traded during trading, an increase of 12% from the previous session's volume of 79,583 shares.The stock last traded at $10.91 and had previously closed at $10.92.

Wall Street Analyst Weigh In

A number of analysts have commented on TLX shares. Citigroup started coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a "buy" rating and a $22.00 price objective for the company. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a "strong-buy" rating in a research report on Monday, October 6th. Weiss Ratings reiterated a "sell (d)" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Finally, HC Wainwright lowered their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $21.00.

Telix Pharmaceuticals Price Performance

The company's 50-day simple moving average is $10.30 and its 200 day simple moving average is $14.05.

Hedge Funds Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC purchased a new position in Telix Pharmaceuticals in the 1st quarter valued at approximately $170,000. IHT Wealth Management LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at approximately $213,000. Blair William & Co. IL purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at approximately $217,000. Vanguard Personalized Indexing Management LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at approximately $297,000. Finally, ABC Arbitrage SA purchased a new position in Telix Pharmaceuticals in the 1st quarter valued at approximately $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.